TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 1 mg | In stock | $ 95 | |
| 2 mg | In stock | $ 161 | |
| 4 mg | In stock | $ 239 | |
| 10 mg | In stock | $ 498 | |
| 20 mg | In stock | $ 791 |
| Description | TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295). |
| Targets&IC50 | p38 MAPK:20 nM |
| In vitro | TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such asMAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C õexpression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro. |
| Synonyms | TA 02, TA02 |
| CAS No. | 1784751-19-4 |
| Chemical Formula | C20H13F2N3 |
| Molecular Weight | 333.342 |
| Solubility | DMSO: ≥ 34 mg/mL (83.67 mM) |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
